Press Releases

HPTN 094 Study Examines a Novel Way to Take Addiction Care and HIV Prevention to People Who Inject Drugs

Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Women—Findings from HPTN 084 Study

HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention

HIV Prevention Trials Network Launches HPTN 094 (INTEGRA) Study

Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains

HPTN Awarded U.S. National Institutes of Health Funding to Continue Research Agenda

HPTN 084 Study Demonstrates Superiority of CAB LA to Oral TDF/FTC for the Prevention of HIV

HPTN 083 Study Demonstrates Superiority of Cabotegravir for the Prevention of HIV

Engaging Disenfranchised U.S. Populations into HIV Care Helps Suppress the Virus